AOD-9604 in Guilvinec — Fat Loss Peptide Research Guide
AOD-9604 research guide for Guilvinec. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
AOD-9604 isn't found on pharmacy shelves in Guilvinec or virtually any local market — this is a specialist compound supplied via a dedicated online market. This matters because AOD-9604 quality ranges widely across the market — from pharmaceutical-grade 99%+ purity to products with serious contamination — and the vendor is the entire quality system. A properly operating AOD-9604 supplier's COA should include HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all batch-matched to your order. This guide walks Guilvinec researchers through that evaluation process and explains what quality documentation for AOD-9604 should look like.
What Studies Say About AOD-9604
AOD-9604 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Guilvinec studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
AOD-9604 Purchasing Guide
Quality AOD-9604 sourcing begins with a useful first test: does this vendor share complete COA data without being asked? Those who make this data freely available are demonstrating research-grade standards. Mass spectrometry in the COA confirms that the main HPLC peak is actually AOD-9604 and not a different peptide of similar polarity — HPLC purity alone cannot verify molecular identity. For Guilvinec researchers evaluating unfamiliar vendors: a modest first purchase to test the product before placing larger orders is what experienced peptide researchers consistently do. For Guilvinec researchers making a first AOD-9604 purchase: verify the vendor against this framework, begin with a small order, and confirm the COA batch number matches your received product before use.
Order AOD-9604 — ships to Guilvinec
COA-verified · International tracking · Research grade
AOD-9604 is supplied strictly for research applications and is not approved for human therapeutic use by the FDA or comparable health authorities — all information here is provided for educational purposes. Proper handling of AOD-9604 requires strict sterile technique during reconstitution — prep pad-cleaned septum, single-use needles, uncontaminated workspace — and cold chain maintenance from receipt through use. Verify the endotoxin level in your AOD-9604 batch COA before any injectable research application — look for results expressed as EU/mg or EU/mL and verify they are within the acceptable range for your research context. For any individual considering AOD-9604 outside a formal research context: consult a qualified physician — this compound is unapproved for human therapeutic application and its safety characterisation does not match that of regulated drugs.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
